Thanks for this. CTC levels are the secondary
Post# of 148184
CTC levels are the secondary endpoint which is supposed to serve as a surrogate endpoint for accelerated approval; Phase 4 study would be done to confirm that reduction below <5 indicates longer PFS and OS, which is statistically likely, espeially if at 0.
With CTC levels at 0 and shrinkage of primary tumour, it seems reasonably likely that FDA will grant AA if we show them good enough data from enough patients.